Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
27,467,750
-
Total 13F shares
-
11,741,328
-
Share change
-
+2,148,463
-
Total reported value
-
$99,891,167
-
Price per share
-
$8.50
-
Number of holders
-
30
-
Value change
-
+$18,097,549
-
Number of buys
-
11
-
Number of sells
-
28
Institutional Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q2 2023
As of 30 Jun 2023 AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) had 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 11,741,328 shares of stock of the company.
Largest 10 holders included RA CAPITAL MANAGEMENT, L.P., BVF INC/IL, CITADEL ADVISORS LLC, TCG Crossover Management, LLC, JANUS HENDERSON GROUP PLC, Octagon Capital Advisors LP, Avidity Partners Management LP, VANGUARD GROUP INC, Monashee Investment Management LLC, and CITIGROUP INC.
This table shows 30 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.